Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
about
ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitorsALK-rearrangements and testing methods in non-small cell lung cancer: a reviewNanotechnology applications in hematological malignancies (Review).Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growthAdvances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.ALK gene alterations in cancer: biological aspects and therapeutic implications.Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922Targeting ALK: Precision Medicine Takes on Drug Resistance.The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.
P2860
Q27310990-A2926EDA-2A08-4B9C-B492-DB4283D9E88AQ33776835-5AEEA77A-3438-4F91-B8D4-68B916E36050Q35934466-20F72019-3716-4720-B0B2-02157DFE7F39Q36106068-C92ADE5B-C86B-4610-8A36-262268105B46Q38307616-7606D549-BE55-4A30-A238-E740BE4650DCQ38756797-4642B19C-0C15-4ECE-975C-C0E1E13AB542Q38767006-01AE1442-8372-4A5E-B309-8403B6F1A022Q38870250-2B729C18-5E08-4037-A7B5-2F216FD93DB5Q38902511-26B3D218-C884-4176-A1A8-A925136C7A40Q39103431-03E31A26-C9B8-4FE1-9007-2BB83BBCA67FQ41116766-C79818F1-8460-4BFC-ACC4-ACF17D901E3AQ41133791-8F8070FA-F8FF-4E4B-944A-5478D0C20BEBQ42199612-3B3EE7B7-C7E8-48B2-B6A6-B6CD2DFB51EFQ42385390-402B4C76-7780-475A-9E1F-EC05080B3C08Q42429703-10A27BCB-8F32-491C-AA7D-3B5BFE7B8E6CQ47895445-51BF6E5D-ABA6-4CAE-9AAA-D76092F63A35Q52671466-D0323233-BB66-47AF-A068-44D1188D7CC5
P2860
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Activating mutations in ALK ki ...... anaplastic large-cell lymphoma
@en
type
label
Activating mutations in ALK ki ...... anaplastic large-cell lymphoma
@en
prefLabel
Activating mutations in ALK ki ...... anaplastic large-cell lymphoma
@en
P2093
P2860
P1476
Activating mutations in ALK ki ...... anaplastic large-cell lymphoma
@en
P2093
Anna Bujak
Barbara Dymek
Daria Zdzalik
Karolina Dzwonek
Maciej Wieczorek
Monika Lamparska-Przybysz
Paulina Grygielewicz
Pawel Gunerka
P2860
P2888
P304
P356
10.1007/S00432-014-1589-3
P577
2014-02-08T00:00:00Z